Blue Jet Healthcare Ltd
Blue Jet Healthcare Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum.
From Blue Jet Healthcare Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. 200 crore per quarter.
- Contrast media segment depressed in H1 FY'25 but rebounded in H2; new product validations including NCE molecules contributing to growth expected in FY'26 and FY'27 (e.g., iodinated intermediate expected to ramp up fully in FY'27).
- PI-API segment grew by 388% YoY, driven by advanced intermediates in cardiovascular therapy; order book fully served with new capacity at Ambernath.
- Europe and Latin America markets for cardiovascular molecules growing faster than in the US.
- Overall revenue grew 45% in FY'25; company aims to sustain growth momentum with strong customer demand, multi-year contracts, and capacity headroom.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs. 300 crores fresh CAPEX planned in FY'25, including upgrades at Unit-2 Ambernath and Mahad.
- Additional capacity being built at Mahad Unit-3, a continuous plant for KSM making, expected to go live in H2 FY'26.
- Multipurpose Plant (MPP) under construction in Mahad, highly automated with ~30 reactors, capacity expected by second half of FY'27; CAPEX for MPP revised upwards to ~Rs. 300 crores.
- State-of-the-art R&D center being built in Hyderabad at Rs. 40 crores, focusing on peptides, GLP-1 intermediates, biocatalysts.
- Acquisition of land in GIDC Dahej, Gujarat for further expansion for CMI and pharma intermediates; timelines not yet firm.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current order book for pharma intermediates is fully served with new capacity added at Ambernath, resulting in a 388% jump compared to FY'24.
- Supplies for an NCE molecule started in Q4, with expected linear order book growth aligned with this molecule's growth.
- The iodinated intermediate is expected to launch in H1 FY'26, with full potential realization anticipated in FY'27.
- Discussions with customers provide good demand visibility; the Company bases volume supply on these forecasts, not on external speculations.
- Cardiovascular intermediate capacity utilization is about 60%-65%, indicating room for growth and readiness to capture demand upticks.
2 more points management made on order book & pipeline
Blue Jet Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹235 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Blue Jet Healthcare Ltd Q4 FY25 results?
Cardiovascular intermediate molecule showing strong growth, with 9,000 cardiologists in the US prescribing it and expansion into new markets like Canada; expected to grow from a new base of Rs. Blue Jet Healthcare reported a strong FY'25 with revenue growth of 45% YoY, EBITDA up 65%, and PAT up 87%, indicating solid earnings momentum.
What is Blue Jet Healthcare Ltd share price analysis?
Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Healthcare Ltd planning capital expenditure?
Rs.
Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.